Dasatinib Accordpharma Europäische Union - Deutsch - EMA (European Medicines Agency)

dasatinib accordpharma

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastische mittel - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.

Abiraterone Accord Europäische Union - Deutsch - EMA (European Medicines Agency)

abiraterone accord

accord healthcare s.l.u. - abirateronacetat - prostata-neoplasmen - endokrine therapie - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Sitagliptin Accord Europäische Union - Deutsch - EMA (European Medicines Agency)

sitagliptin accord

accord healthcare s.l.u. - sitagliptin hydrochloride - diabetes mellitus, typ 2 - drogen bei diabetes verwendet - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Daptomycin Accord 350 mg Pulver zur Herstellung einer Injektions-/Infusionslösung Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

daptomycin accord 350 mg pulver zur herstellung einer injektions-/infusionslösung

accord healthcare b.v. (8182087) - daptomycin - pulver zur herstellung einer injektions-/infusionslösung - teil 1 - pulver zur herstellung einer injektions-/infusionslösung; daptomycin (24575) 350 milligramm

Daptomycin Accord 500 mg Pulver zur Herstellung einer Injektions-/Infusionslösung Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

daptomycin accord 500 mg pulver zur herstellung einer injektions-/infusionslösung

accord healthcare b.v. (8182087) - daptomycin - pulver zur herstellung einer injektions-/infusionslösung - teil 1 - pulver zur herstellung einer injektions-/infusionslösung; daptomycin (24575) 500 milligramm